Small Samples, Protocol Delays Mar FDA’s Use Of Postapproval Studies
This article was originally published in The Gray Sheet
Executive Summary
Small sample sizes and delays in reaching protocol agreements are hindering FDA’s ability to use postapproval study data to track device performance, says a study in JAMA Internal Medicine.